Nuvation Bio Inc (NUVB NYSE) stock market data APIs
$8.5439
-0.23(-2.7%)
as of December 5, 2025
Try our APIs with
free plan!
Nuvation Bio Inc Financial Data Overview
Price chart is built with
Anychart
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
Prev. Close
8.5439
Open
8.3187
High
8.6913
Low
8.1691
52 wk Range
1.54-8.7
Market Cap
2 931 M
Shares Outstanding
342 M
Revenue
26 748 K
EPS
-0.16
Beta
1.587
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Nuvation Bio Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nuvation Bio Inc data using free add-ons & libraries
Get Nuvation Bio Inc Fundamental Data
Nuvation Bio Inc Fundamental data includes:
- Net Revenue: 26 748 K
- EBITDA: -231 550 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-03
- EPS/Forecast: -0.17
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nuvation Bio Inc News
New
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
SAN FRANCISCO and SUZHOU, China, Dec. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerciali...
Nuvation Bio Shares Rise 8.4% After Positive Phase 2 Results In Grade-2 IDH1 Glioma
(RTTNews) - Nuvation Bio Inc. (NUVB) climbed 8.43%, rising $0.63 to $8.10, following the publication of favorable Phase 2 clinical trial results for its drug safusidenib in patients with grade-2 IDH1-...
Top Growth Companies With Strong Insider Ownership November 2025
As the U.S. stock market experiences a robust week, buoyed by gains across major indices like the Dow Jones and Nasdaq despite recent technical disruptions, investors are keenly observing growth trend...
Nuvation Bio to discontinue development of NUV-1511
[Tumor microenvironment concept with cancer cells, T-Cells, nanoparticles, cancer associated fibroblast layer of tumor microenvironment normal cells, molecules, and blood vessels] CIPhotos Nuvation B...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
